INSYGMA NUTRITIONGlyNAC: The promising combination?
GlyNAC combines glycine and N-acetylcysteine. Small human trials have investigated effects on cellular defense, metabolism, physical function and cognition. The results are promising, but the size and duration of the studies limit what we can conclude.
The thesis in 20 seconds
It's a combination of glycine and N-acetylcysteine made to give the body two essential pieces to produce glutathione — one of the cell's main internal defenses. What makes GlyNAC rare isn't improving a single isolated marker. It's showing up, repeatedly, improving several important areas at the same time, with no adverse effects reported in the studies analyzed.[1][2]
In a 16-week trial, 24 older adults were assigned to GlyNAC or placebo. The GlyNAC group showed improvements in several metabolic markers and measures of physical function. The findings on hallmarks of aging were exploratory; they do not demonstrate longer life or guarantee benefits in healthy people of other ages.[1]
The pattern that repeats
Rather than looking at each study in isolation, the right way to read it is to see the full pattern. The literature on GlyNAC shows a simple sequence: the body restores glutathione, oxidative stress drops, mitochondria work better, metabolism follows suit and the person gains signs of better function.
This is the point that sets GlyNAC apart from an ordinary supplementation promise. We're not talking about a nice-looking marker on a chart. We're talking about a broad improvement that shows up in older adults, type 2 diabetes, HIV/premature aging and states of elevated oxidative stress.[3][4][5]
The evidence map
The literature doesn't just show “improvements.” It shows a consistent direction. Across various contexts, GlyNAC pushes the body in the same direction: more cellular defense, less oxidative damage, better energy, better metabolism and better physical function.
The short table: what really matters
| Human context | The initial problem | What improved | Reading |
|---|---|---|---|
| Older adults — RCT | Low glutathione, high oxidative stress, worse cellular energy, inflammation, insulin resistance, worse physical function and hallmarks of aging. | Improved/corrected multiple defects vs placebo. | Centerpiece |
| Older adults — 24 weeks | The same axis: cellular defense, oxidative stress, energy, mental function, strength and body composition. | Improved with use; part regressed after withdrawal. | Biological signal |
| Type 2 diabetes | Poorer use of fat for energy, greater dependence on glucose, elevated insulin resistance, and high free fatty acids. | +30% in fat use as energy, -47% in glucose oxidation, -22% in insulin resistance and -25% in free fatty acids in 14 days. | Metabolic |
| HIV / premature aging | Oxidative stress, cellular energy, inflammation, vessel health, insulin resistance, physical function and mental function. | Improved during GlyNAC; several benefits declined after withdrawal. | Replication |
| Hospitalized COVID-19 | Severely low glutathione, elevated oxidative stress and oxidative damage. | It didn't test GlyNAC as an intervention. | Redox context |
Because NAC alone doesn't tell the whole story
The objection is obvious: if GlyNAC works through glutathione, why not just take NAC?
The problem isn't NAC. The problem is expecting NAC alone to resolve a pathway that also depends on glycine. GlyNAC is more interesting because it addresses the bottleneck more completely.
The point almost no one understands
GlyNAC's strength isn't “boosting antioxidants.” It's helping the cell recover a defense it should have had all along.
This is different from taking an external antioxidant and hoping it fixes everything. GlyNAC provides raw material. Then the cell does what it knows how to do: produce glutathione, protect energy production, lower oxidative stress and regain efficiency.
The cited trials reported good tolerability during the study period. In the 16-week trial, no adverse events related to GlyNAC or placebo were reported. Small samples and limited follow-up cannot rule out rare effects or establish safety for everyone or over the long term.[1][2]
A promising combination that deserves larger studies.
The cited studies observed improvements in several areas, mainly in older adults and specific populations. Many are pilot or open-label studies; larger, independent trials are needed to confirm clinical relevance and long-term safety.
GlyNAC simultaneously touches on cellular defense, oxidative stress, cellular energy, inflammation, insulin resistance, blood vessel health, strength, gait, mental function, body composition and biological hallmarks of aging.[1][2][3]
In the randomized trial in older adults, the authors highlight a rare point: several compounds had already improved some hallmarks of aging in non-human models, but there were no reports of improvement across multiple hallmarks of aging in a randomized clinical trial in humans. GlyNAC did that.[1]
GlyNAC deserves scientific attention because of the connection between glutathione precursors, metabolism and cellular function. The next step is to confirm these signals in larger studies, without turning them into a promise of rejuvenation or a guaranteed outcome of supplementation.
- Kumar, P. et al. (2023). Supplementing Glycine and N-Acetylcysteine (GlyNAC) in Older Adults Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Physical Function, and Aging Hallmarks: A Randomized Clinical Trial. Journals of Gerontology: Medical Sciences, 78(1), 75–89. PubMed
- Sekhar, R. V. (2021). GlyNAC Supplementation Improves Glutathione Deficiency, Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Aging Hallmarks, Metabolic Defects, Muscle Strength, Cognitive Decline, and Body Composition: Implications for Healthy Aging. The Journal of Nutrition, 151(12), 3606–3616. PubMed
- Kumar, P. et al. (2021). Glycine and N-acetylcysteine (GlyNAC) supplementation in older adults improves glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength, and cognition: Results of a pilot clinical trial. Clinical and Translational Medicine, 11, e372. PubMed
- Sekhar, R. V. (2022). GlyNAC (Glycine and N-Acetylcysteine) Supplementation Improves Impaired Mitochondrial Fuel Oxidation and Lowers Insulin Resistance in Patients with Type 2 Diabetes: Results of a Pilot Study. Antioxidants, 11(1), 154. PubMed
- Kumar, P. et al. (2020). Supplementing Glycine and N-acetylcysteine (GlyNAC) in Aging HIV Patients Improves Oxidative Stress, Mitochondrial Dysfunction, Inflammation, Endothelial Dysfunction, Insulin Resistance, Genotoxicity, Strength, and Cognition: Results of an Open-Label Clinical Trial. Biomedicines, 8(10), 390. PubMed
- Kumar, P. et al. (2022). Severe Glutathione Deficiency, Oxidative Stress and Oxidant Damage in Adults Hospitalized with COVID-19: Implications for GlyNAC (Glycine and N-Acetylcysteine) Supplementation. Antioxidants, 11(1), 50. PubMed